- Home
- AKBA vs IIIV Comparison
AKBA vs IIIV Comparison
Compare AKBA & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- IIIV
- Stock Information
- Founded
- AKBA 2007
- IIIV 2012
- Country
- AKBA United States
- IIIV United States
- Employees
- AKBA N/A
- IIIV N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- AKBA Health Care
- IIIV Technology
- Exchange
- AKBA Nasdaq
- IIIV Nasdaq
- Market Cap
- AKBA 729.1M
- IIIV 720.4M
- IPO Year
- AKBA 2014
- IIIV 2018
- Fundamental
- Price
- AKBA $1.68
- IIIV $29.33
- Analyst Decision
- AKBA Strong Buy
- IIIV Buy
- Analyst Count
- AKBA 6
- IIIV 6
- Target Price
- AKBA $6.25
- IIIV $34.33
- AVG Volume (30 Days)
- AKBA 5.5M
- IIIV 155.6K
- Earning Date
- AKBA 11-10-2025
- IIIV 11-17-2025
- Dividend Yield
- AKBA N/A
- IIIV N/A
- EPS Growth
- AKBA N/A
- IIIV N/A
- EPS
- AKBA N/A
- IIIV 5.56
- Revenue
- AKBA $225,071,000.00
- IIIV $248,271,000.00
- Revenue This Year
- AKBA $53.38
- IIIV N/A
- Revenue Next Year
- AKBA $30.53
- IIIV $3.86
- P/E Ratio
- AKBA N/A
- IIIV $5.28
- Revenue Growth
- AKBA 32.49
- IIIV 25.08
- 52 Week Low
- AKBA $1.52
- IIIV $22.20
- 52 Week High
- AKBA $4.08
- IIIV $33.97
- Technical
- Relative Strength Index (RSI)
- AKBA 24.68
- IIIV 34.90
- Support Level
- AKBA $2.07
- IIIV $29.19
- Resistance Level
- AKBA $3.19
- IIIV $30.98
- Average True Range (ATR)
- AKBA 0.16
- IIIV 1.05
- MACD
- AKBA -0.09
- IIIV -0.31
- Stochastic Oscillator
- AKBA 6.19
- IIIV 3.93
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.